Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.

doi:10.1038/s42003-020-1042-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.

Communications biology - 16 Jun 2020

Savage Paul, Pacis Alain, Kuasne Hellen, Liu Leah, Lai Daniel, Wan Adrian, Dankner Matthew, Martinez Constanza, Muñoz-Ramos Valentina, Pilon Virginie, Monast Anie, Zhao Hong, Souleimanova Margarita, Annis Matthew G, Aguilar-Mahecha Adriana, Lafleur Josiane, Bertos Nicholas R, Asselah Jamil, Bouganim Nathaniel, Petrecca Kevin, Siegel Peter M, Omeroglu Atilla, Shah Sohrab P, Aparicio Samuel, Basik Mark, Meterissian Sarkis, Park Morag

Abstract excerpt

Subsets of breast tumors present major clinical challenges, including triple-negative, metastatic/recurrent disease and rare histologies. Here, we developed 37 patient-derived xenografts (PDX) from these difficult-to-treat cancers to interrogate their molecular composition and functional biology. Whole-genome and transcriptome sequencing and reverse-phase protein arrays revealed that PDXs conserve the molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Mice, Inbred NOD

Share to Precision Medicine

Share to Proof of Concept Study

Share to Protein Array Analysis

Share to Whole Genome Sequencing

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32546838
DOI: 10.1038/s42003-020-1042-x
PMCID: PMC7298048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.PMID 32546838Read ↗

An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapySemantic proximity Read ↗

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsSemantic proximity Read ↗

A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancerSemantic proximity Read ↗

The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.Semantic proximity Read ↗

Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancerSemantic proximity Read ↗

Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy ResponseSemantic proximity Read ↗

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic CancerSemantic proximity Read ↗

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesSemantic proximity Read ↗

A comprehensive luminal breast cancer patient‐derived xenografts ( PDX ) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4 /6 inhibitorsSemantic proximity Read ↗

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast CancerSemantic proximity Read ↗

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.Semantic proximity Read ↗

An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.